Skip to main content

Table 1 Baseline Characteristics among 241 HIV-infected children who received second-line protease inhibitor –based antiretroviral therapy

From: High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting

Characteristics

All (n = 241)

Single-boosted PIRegimens1(n = 104)

Double-boosted PI regimens1(n = 137)

P-value

Gender: Male

117 (49)

55 (53)

62 (45)

0.24

Age, years

9.1 (7.2-11.1)

8.9 (6.1-11.1)

9.4 (7.6-11.2)

0.046

Prior to initiate NNRTI regimen

CDC clinical staging

   

0.04

 N

10 (4.2)

7 (6.7)

3 (2.2)

 

 A

58 (24.3)

29 (27.9)

29 (21.6)

 

 B

113 (47.3)

39 (37.5)

74 (54.8)

 

 C

58 (24.3)

29 (27.9)

29 (21.5)

 

CD4 percentage

5 (1–10)

3.5 (1–11)

5 (2–10)

0.53

CD4 cell/mm3

109 (27–410)

109 (21–395)

112 (28–413)

0.51

Prior to switch to second-line boosted -PI regimen

Weight for age Z-score

−1.7 (−2.1 to −0.9)

−1.4 (−1.9 to −0.7)

−1.9 (−2.3 to −1.4)

<0.001

CD4% (n = 239)

10 (4–18)

17 (7–24)

6 (2–12)

<0.001

CD4 cell/mm3 (n = 238)

195 (70–442)

379 (165–659)

123 (38–273)

<0.001

HIV RNA, log 10 copies/mL (n = 227)

4.8 (4.3-5.3)

4.5 (3.9-5.1)

4.9 (4.5-5.4)

<0.001

Antiretroviral treatment history

Mono/dual NRTI exposure prior to NNRTI-based regimen

71 (29.5)

23 (22.1)

48 (35.0)

0.03

Duration on NNRTI-based treatment, years

2.2 (1.5-2.9)

2.3 (1.5-3.1)

2.0 (1.4-2.9)

0.04

NNRTI regimen

   

0.01

 Nevirapine

167 (69.3)

81 (77.9)

86 (62.8)

 

 Efavirenz

74 (30.7)

23 (22.1)

51 (37.2)

 

NRTI-backbone

    

 d4T/3TC

142(58.9)

71 (68.2)

71 (51.8)

0.015

 AZT/3TC

60 (24.9)

25(24.0)

35(25.6)

 

 d4T/ddI

17 (7.1)

4 (3.9)

13(9.5)

 

 AZT/ddI

14(5.8)

3(2.9)

11(8.0)

 

 ddI/3TC

8 (3.3)

1 (1.0)

7 (5.1)

 

Multi-NRTI resistance2

   

<0.001

 No TAMs

45/203(22.2)

38/89 (42.7)

7/114 (6.1)

 

 Low grade multi-NRTI

78/203 (38.4)

40/89 (44.9)

38/114 (33.3)

 

 High grade multi-NRTI

80/203 (39.4)

11/89 (12.4)

69/114 (60.5)

 
  1. Data are presented in median (IQR) or number (%).
  2. 1Single boosted PI regimens include ritonavir-boosted Protease inhibitor plus 2 nucleoside reverse transcriptase. Double-boosted PI regimens included 2 protease inhibitors plus ritonavir with/without NRTI/NNRTI.
  3. 2Definition of multi NRTI resistance: high grade is defined as ≥ 4 thymidine analog associated mutations (TAMs) or the presence of Q151M or 69Insertion. Low grade multi NRTI resistance is defined as 1–3 TAMs and without Q151M and 69insertion.
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us